| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Specific molecular targets of Hymexelsin have not been extensively characterized. As a coumarin glycoside found in Hymenodictyon excelsum, it may share biological activities with other coumarins, including antioxidant, anti-inflammatory, and antimicrobial properties. The compound contains a scopoletin (6-methoxycoumarin) core, which is known for various biological activities. However, specific molecular targets have not been identified in the available literature. Further studies are needed to elucidate its mechanism of action.
|
|---|---|
| ln Vitro |
In vitro activity data for Hymexelsin are limited in the published literature. The compound has been primarily characterized as a natural product from Hymenodictyon excelsum. As a coumarin glycoside, it may exhibit antioxidant, anti-inflammatory, or antimicrobial activities in cell-based assays. However, detailed in vitro activity data including IC₅₀ values have not been extensively published. The compound is a structurally complex coumarin glycoside with an apiose sugar moiety.
|
| ln Vivo |
In vivo activity data for Hymexelsin are not available in the published literature. The compound has been primarily characterized as a natural product from Hymenodictyon excelsum. No in vivo pharmacological studies have been reported for this compound. Further research is needed to evaluate its potential biological activities in animal models. The compound's natural occurrence in the stem bark of H. excelsum suggests it may have ecological or physiological roles in the source plant.
|
| Enzyme Assay |
In vitro assays for Hymexelsin are not extensively documented. As a coumarin glycoside, potential assays could include antioxidant activity evaluation using DPPH or ABTS radical scavenging assays, anti-inflammatory activity by measuring cytokine production in immune cells, and antimicrobial activity using broth microdilution or disc diffusion methods. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC. The compound is stored as a powder at -20°C for 3 years or 4°C for 2 years.
|
| Cell Assay |
In vitro cellular assays for Hymexelsin are not extensively documented. Potential cellular assays could include evaluation of antioxidant activity in cell-based oxidative stress models, anti-inflammatory activity in macrophages or other immune cells, and cytoprotective effects. Cells are treated with the compound and cell viability, reactive oxygen species levels, or cytokine production is measured. The compound is typically handled as a powder and may be soluble in appropriate solvents for cell culture applications.
|
| Animal Protocol |
In vivo animal experiments for Hymexelsin have not been reported in the published literature. The compound has been studied primarily as a natural product from Hymenodictyon excelsum. No animal studies have been conducted to evaluate its pharmacological effects, toxicity, or pharmacokinetics. Further research would be required to investigate its potential therapeutic applications in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Hymexelsin have not been characterized. The compound has a molecular weight of 486.42 g/mol and a molecular formula of C₂₁H₂₆O₁₃. As a glycosylated coumarin with a disaccharide moiety (apiose-glucose), it is expected to have limited oral bioavailability due to its hydrophilic nature. The compound may undergo deglycosylation in the gastrointestinal tract to release the active aglycone. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Hymexelsin has not been extensively documented. As a naturally occurring coumarin glycoside from Hymenodictyon excelsum, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Hymexelsin (Xeroboside) (CAS# 117842-09-8, molecular formula C₂₁H₂₆O₁₃, molecular weight 486.42) is a naturally occurring apiose-containing scopoletin glycoside from Hymenodictyon excelsum. Also known as 7-O-[beta-D-apiofuranosyl-(1->6)-beta-D-glucopyranosyl]-6-methoxycoumarin. No clinical trials or regulatory approvals have been identified. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Molecular Formula |
C21H26O13
|
|---|---|
| Molecular Weight |
486.42
|
| Exact Mass |
486.137
|
| CAS # |
117842-09-8
|
| PubChem CID |
189520
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
818.7±65.0 °C at 760 mmHg
|
| Flash Point |
284.9±27.8 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.672
|
| LogP |
-0.46
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
748
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC2C=CC(OC=2C=C1OC1OC(COC2OCC(O)(CO)C2O)C(O)C(O)C1O)=O
|
| InChi Key |
DCERMUGUBKSKBM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H26O13/c1-29-11-4-9-2-3-14(23)32-10(9)5-12(11)33-19-17(26)16(25)15(24)13(34-19)6-30-20-18(27)21(28,7-22)8-31-20/h2-5,13,15-20,22,24-28H,6-8H2,1H3
|
| Chemical Name |
7-[6-[[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methoxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0558 mL | 10.2792 mL | 20.5584 mL | |
| 5 mM | 0.4112 mL | 2.0558 mL | 4.1117 mL | |
| 10 mM | 0.2056 mL | 1.0279 mL | 2.0558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
